Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02704871 · ClinicalTrials.gov registry record
The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS
A clinical trial, sponsored by Immunexpress.
- Terminated
- Registry status
- 66
- Enrollment target
NCT02704871: Clinical Trial study, sponsored by Immunexpress.
NCT02704871 is a clinical trial that was terminated before completion, run by Immunexpress. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02704871 was terminated before completion, sponsored by Immunexpress.
- TERMINATED
- Registry status
- 66 participants
- Enrollment target
Study Summary
A non-interventional, prospective observational study to assess the performance of SeptiCyte® Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS
Primary Outcome
To validate the ability of the SeptiCyte® Lab test to correctly discriminate infection positive from infection negative SIRS in hospital ward patients with two or more SIRS criteria compared to the non-reference method of retrospective physician diagnosis (RPD).
Interventions
- OTHER SeptiCyte Lab molecular diagnostic test (non-interventional)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-02 |
Why NCT02704871 stopped before completion
NCT02704871 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 66 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SeptiCyte Lab molecular diagnostic test (non-interventional) is the first listed.
NCT02704871 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02704871 about?
NCT02704871 is a clinical study titled "The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS". A non-interventional, prospective observational study to assess the performance of SeptiCyte® Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS
What is the current status of trial NCT02704871?
This trial is currently terminated. The enrollment target is 66 participants. The study started on 2015-06. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02704871?
The interventions under investigation include: SeptiCyte Lab molecular diagnostic test (non-interventional) (OTHER).
Who is sponsoring clinical trial NCT02704871?
This trial is sponsored by Immunexpress, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia